Plain-English translation of NCT07215390 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called APL-3007 combined with an existing eye injection treatment called Syfovre (pegcetacoplan) for people with geographic atrophy, a condition that causes progressive vision loss in the central part of the eye due to aging. Researchers want to see if adding this medication to the injections you may already be receiving can slow down the vision loss better than the injection alone. The study will compare the new medication at different doses against a placebo (inactive treatment) to find the best approach.
Geographic atrophy is a serious form of age-related macular degeneration that currently has limited treatment options. While Syfovre injections have helped some patients, doctors are looking for ways to make the treatment even more effective by combining it with this medication to better protect remaining vision.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will continue receiving your regular Syfovre eye injections and will also receive either the new medication APL-3007 or a placebo through injections under the skin at different dose schedules. You'll visit the study clinic multiple times for eye exams, imaging scans, and blood work to monitor your vision and how your eyes respond to the treatment. The study involves about 240 people across multiple clinics, and your participation will help researchers determine whether this combination treatment works better than the injection alone.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States